Fujifilm is helping make the world a better, healthier, and more interesting place. Learn more about what we’re about.
L to R: Adrian Waller – General Manager at Fujifilm Medical Systems UK, Tracy Finlayson – Team Leader for Women’s Health
The final stage of approval for Fujifilm’s AMULET Innovality mammography system has been confirmed by NHS Breast Screening Programme (NHSBSP). Following both a technical and practical evaluation at Burnley Hospital, the AMULET Innovality is now approved for tomosynthesis in Assessment (screening) clinics in England.
Fujifilm delivered the first dual angle digital breast tomosynthesis (DBT) to the market, and the AMULET Innovality remains the only mammography system which combines screening and symptomatic tomosynthesis functionality in a single system. It offers a range of patient comfort features, which include the Fit Sweet compression paddle, Comfort Comp technology which activates controlled decompression during acquisition, and very fast workflow times which mean less time in compression for patients.
We are absolutely delighted that the unique technologies, low dose and patient comfort features which Fujifilm offer will now be available to screening clinics in England for the first time. The AMULET Innovality is already used with tomosynthesis for Assessment across Wales, and has also been very popular with the independent sector due to its image quality and patient comfort features. It is proven to be an extremely reliable system, with recorded uptime of 99.99% in 2018 for all installations across the UK. Fujifilm is committed to improving screening and detection of breast cancer in the UK, and the NHSBSP approval means we can now help to enhance patient experience and support clinicians across the UK.
Fujifilm Corporation is a wholly-owned subsidiary of Fujifilm Holdings Corporation.